Article Sidebar
Published:
Feb 9, 2021DOI:
10.4314/aas.v18i1.5Keywords:
Article Details
Authors submitting articles to The Annals of African Surgery do so on the understanding that if accepted, they will retain the copyright and allow the journal to publish and archive the article under the CC BY (Creative Commons Attribution License) 4.0 International. See details on the Creative commons website. All authors will be required to sign an Author Agreement form detailing the agreement with the journal prior to the article being published. Download the form here
This work is licensed under the Creative Commons Attribution 4.0 International License.
Main Article Content
Predicting Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer in Kenya: Utility of Ki67
Abstract
Background: Ki67 levels have been shown to have good predictive value in breast cancer treatment. There is paucity of data on Ki67 levels in predicting response to neoadjuvant chemotherapy (NACT) in Kenya. This study evaluated the utility of Ki67 in predicting response to NACT.
Methods: This was a prospective observational study carried out at Kenyatta National Hospital between December 2017 and January 2019 on
patients with locally advanced breast cancer. We recruited 61 women through consecutive sampling technique. Data collected included patient demographics, pre-treatment tumor size, Ki67 levels and tumor biology. After 3 cycles of first-line chemotherapy, ultrasonography was used to determine response. Data were analyzed by SPSS for proportion of change in tumor size. The response was correlated with tumor biology and pretreatment levels of Ki67 using chisquare at a 95% confidence interval. A p-value <0.05 was considered statistically significant.
Results: The response rate after 3 cycles of NACT was 39.4%, sensitivity and specificity of Ki67 levels were 70.8% and 43.2% respectively with a cut-off value of 32.5%.
Conclusions: Ki67 was found to predict response in our context at a rate of 39.4% at 20% cutoff after 3 cycles.
Keywords: Ki67, Breast cancer, Neoadjuvant chemotherapy
